Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with ...

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is ...

How would you summarize your study for a lay audience?Heart failure remains a substantial burden for patients due to its high ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...